VC Deals
Editas Medicine, a Cambridge, Mass.-based genome editing company, has raised $120 million in Series B funding. Boris Nikolic led the round, on behalf of a U.S. investment company formed by several family offices to invest exclusively in Editas Medicine. Other backers include Deerfield Management, Viking Global Investors, Fidelity Management & Research Co., T. Rowe Price, Google Ventures, Jennison Associates, Khosla Ventures, EcoR1 Capital, Casdin Capital, Omega Funds, Cowen Private Investments and Alexandria Venture Investments. Return participants included Flagship Ventures, Polaris Partners and Third Rock Ventures
Sentien Biotechnologies Inc., a Medford, Mass.-based regenerative medicine company focused on acute organ failure, has raised an undisclosed amount of Series A funding from Boehringer Ingelheim Venture Fund USAand Portage Biotech Inc
GeneriCo LLC, a St. Louis-based developer of niche generic drugs with embedded drug delivery technology, has raised $1.5 million in Series A funding (round remains open with $2m target). Kinsale Capital Partnersled the first close, and was joined by BioGenerator and Missouri Technology Corp
Ovid Therapeutics Inc., a New York-based developer of therapies for rare and orphan brain diseases, has raised $75 million in Series B funding. Fidelity led the round, and was joined by Sanofi-Genzyme BioVentures, Tekla Capital Management, Sphera Global Healthcare Fund, Jennison Associates, Redmile Group, Cormorant Asset Management and return backers like DoubleLine Equity Healthcare Fund
Checkmate Pharmaceuticals, a Cambridge, Mass.-based cancer immunotherapy startup, has raised $20 million in Series A funding from Sofinnova Ventures and venBio. The company also said that it has exclusively licensed a validated virus-like particle platform from Cytos Biotechnology Ltd (Swiss: CYTN)
Rhythm Metabolic Inc., a subsidiary of Boston-based Rhythm that is developing a treatment of obesity caused by genetic deficiencies in the MC4 pathway, has raised $40 million in Series A funding. OrbiMed, Deerfield Management, Wellington Management Co. and an undisclosed public healthcare investment fund were joined by return backers MPM Capital, New Enterprise Associates, Third Rock Ventures, Pfizer Ventures and Ipsen
Soothe, a Los Angeles-based on-demand massage company, has $10.6 million in new funding from The Riverside Company
Icebreaker Health, a San Francisco-based telemedicine platform, has raised around $6.6 million in VC funding, according to a regulatory filing. No investors were disclosed
Turing Pharmaceuticals, a year-old, New York-based biopharmaceutical company founded by former hedge fund manager Martin Shkreli, has raised $90 million in Series A funding from Shkreli, along with unnamed equity investors and debt providers. Shkreli has most recently founded a similar company, Retrophin, in 2012 but was ousted from his role as CEO last year
Ovid Therapeutics, a 1.5-year-old, New York-based biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, has raised $75 million in Series B funding led by Fidelity Management & Research Company, with participation from Cowen Private Investments,Sanofi-Genzyme BioVentures, Tekla Capital Management, Sphera Global Healthcare Fund, Jennison Associates, Redmile Group, and Cormorant Asset Management, as well as earlier backer DoubleLine Equity Healthcare Fund
Sarvint Technologies, a year-old, Atlanta, Ga.-based wearables technology company whose “smart shirt” detects and monitors users’ vital signs, has raised $6 million in Series A funding led by CTW Venture Partners, with participation from Monta Vista Capital and Maxim Ventures
IPO Deals
Global Blood Therapeutics Inc., a South San Francisco-based developer of drugs to treat serious blood-based disorders, raised $120 million in its IPO. The company priced 6 million shares at $20 per share (above $16-$18 range), for an initial market cap of around $556 million. It will trade on the Nasdaq under ticker symbol GBT, while Morgan Stanley and Goldman Sachs served as lead underwriters. Shareholders in the pre-revenue company include Third Rock Ventures (63% pre-IPO stake) andFidelity (13.2%)
Other Deals
Premier Inc. (Nasdaq: PINC) has acquired Healthcare Insights LLC, a Libertyville, Ill.-based provider of financial management software for hospitals and healthcare systems, for $65 million in cash
Roche Holding AG has agreed to acquire GeneWeave BioSciences Inc., a Los Gatos, Calif.-based microbiology diagnostics company, for upwards of $425 million (including $190m upfront payment). GeneWeave had raised around $24 million in VC funding from firms like Decheng Capital, Claremont Creek Ventures and XSeed Capital
Sources: Term Sheet, Financial Times, StrictlyVC, TechinAsia, CrunchBase, TechCrunch, Bloomberg
#healthtech #asia
